Adamas Pharmaceuticals, Inc. (ADMS)
| Market Cap | 219.09M |
| Revenue (ttm) | 82.47M |
| Net Income (ttm) | -55.11M |
| Shares Out | 45.46M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,668 |
| Open | 4.83 |
| Previous Close | 4.78 |
| Day's Range | 4.74 - 4.89 |
| 52-Week Range | 2.96 - 9.15 |
| Beta | 2.68 |
| Analysts | Buy |
| Price Target | 8.79 (+80.9%) |
| Est. Earnings Date | Nov 4, 2021 |
About ADMS
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet ...
Financial Performance
In 2020, ADMS's revenue was $74.46 million, an increase of 36.28% compared to the previous year's $54.64 million. Losses were -$57.40 million, -45.43% less than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ADMS stock is "Buy." The 12-month stock price forecast is 8.79, which is an increase of 80.86% from the latest price.
News
Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society's (MDS) ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Announces New Employment Inducement Grants
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricte...
Adamas to Present at Upcoming September Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricte...
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates
Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Adamas Reports Second Quarter 2021 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market clos...
Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted four new employees restricted...
Adamas to Present at Upcoming William Blair Biotech Focus Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options
Investors need to pay close attention to Adamas Pharmaceuticals (ADMS) stock based on the movements in the options market lately.
Adamas to Present at Upcoming SVB Leerink CNS Forum
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricte...
New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's Disease
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas to Present at Upcoming June Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates
Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Adamas Reports First Quarter 2021 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy?
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamas to Present at Upcoming BofA Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyski...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. ...
Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson's disease presented at Americ...
TUCSON, Ariz. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to de...
Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas to Present at Upcoming Needham Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...